Balaxi Pharmaceuticals Q2 FY27 Revenue Jumps 39.4% to ₹80.54 Cr, PAT Soars 450%
Balaxi Pharmaceuticals reported a 39.44% revenue increase to ₹80.54 crore for Q2 FY27. PAT surged 450.33% to ₹1.15 crore. The company added 31 new product registrations in H1 FY27, focusing on Africa and Latin America. The Jadcherla manufacturing facility is now operational.
The substantial revenue growth and impressive PAT increase, coupled with the operationalization of the new manufacturing facility and strategic focus on key markets, are likely to have a significant positive impact on investor sentiment and the company's financial outlook.
The company reported significant year-on-year growth in revenue and a substantial increase in Profit After Tax, indicating strong operational performance and market expansion.
Balaxi Pharmaceuticals Limited announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a significant increase in total revenue for Q2 FY27, reaching ₹8,054.38 lakhs (₹80.54 crore), a 39.44% rise compared to ₹5,776.03 lakhs (₹57.76 crore) in Q2 FY26. EBITDA for the quarter grew by 55.88% to ₹429.23 lakhs (₹4.29 crore), with the EBITDA margin improving by 56 basis points to 5.33%. Profit After Tax (PAT) witnessed a substantial surge of 450.33%, reaching ₹115.02 lakhs (₹1.15 crore) from ₹20.90 lakhs (₹0.21 crore) in the same period last year. Diluted EPS increased by 425% to ₹0.21.
For the half-year ended H1 FY27, total revenue increased by 26.44% to ₹16,023.35 lakhs (₹160.23 crore) compared to ₹12,672.58 lakhs (₹126.73 crore) in H1 FY26. EBITDA for H1 FY27 rose by 55.35% to ₹796.26 lakhs (₹7.96 crore), and PAT saw a remarkable jump of 390.40% to ₹244.76 lakhs (₹2.45 crore). The company highlighted its focus on strengthening its presence in Africa and Latin America through its branded, IPR-driven business model, adding 31 new product registrations in H1 FY27. Latin America continues to be a key growth market, with ongoing efforts to improve operational efficiencies and cash conversion in Angola. The Jadcherla manufacturing facility is now operational, marking the next phase of growth driven by in-house manufacturing, branded generics, and geographical expansion.
What to do with a filing like this
BALAXI PHARMACEUTICALS LIMITED filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by BALAXI PHARMACEUTICALS LIMITED. Read the original for the full detail.